Kiora Pharmaceuticals, Inc.

NasdaqCM:KPRX Stock Report

Market Cap: US$15.8m

Kiora Pharmaceuticals Balance Sheet Health

Financial Health criteria checks 6/6

Kiora Pharmaceuticals has a total shareholder equity of $8.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $15.9M and $7.8M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$5.40m
EquityUS$8.10m
Total liabilitiesUS$7.79m
Total assetsUS$15.90m

Recent financial health updates

Recent updates

Kiora pharmaceuticals regains compliance with Nasdaq minimum bid price requirement

Oct 13

Kiora Pharma announces 1-for-40 reverse stock split

Sep 26

Kiora Pharmaceuticals reports 1H results

Aug 12

Kiora gets US patent for KIO-201 use with antibiotics for eye wound healing

Jul 28

Kiora Pharmaceuticals prices $5.2M underwritten public offering

Jul 22

Kiora begins enrolling in phase 2 trial of wound healing eye drops KIO-201

Jul 05

EyeGate Pharmaceuticals announces $8M private placement

Jan 06

EyeGate surge in premarket as it acquires Panoptes Pharma for $4M

Dec 21

Financial Position Analysis

Short Term Liabilities: KPRX's short term assets ($7.0M) exceed its short term liabilities ($2.1M).

Long Term Liabilities: KPRX's short term assets ($7.0M) exceed its long term liabilities ($5.7M).


Debt to Equity History and Analysis

Debt Level: KPRX is debt free.

Reducing Debt: KPRX had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: KPRX has sufficient cash runway for 7 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: KPRX is forecast to have sufficient cash runway for 7 months based on free cash flow estimates, but has since raised additional capital.


Discover healthy companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.